1391730-27-0

Basic information

• Product Name: tert-butyl (S)-3-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate
• Synonyms: tert-butyl (S)-3-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate
• CAS NO: 1391730-27-0
• Molecular Weight: 355.455
• Mol File: 1391730-27-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl (S)-3-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (S)-3-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate(1391730-27-0)
• EPA Substance Registry System: tert-butyl (S)-3-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate(1391730-27-0)

Safety Data

• Hazardous Substances Data: 1391730-27-0(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 199174-24-8 tert-butyl (3S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate 

Downstream Products

• 274692-07-8 (R)-tert-butyl 3-(cyanomethyl)pyrrolidine-1-carboxylate 
• 1187931-76-5 tert-butyl (S)-3-(cyanomethyl)pyrrolidine-1-carboxylate 
• 890849-28-2 (R)-tert-butyl 3-(2-oxoethyl)pyrrolidine-1-carboxylate 
• 204688-60-8 (R)-3-carboxymethyl-pyrrolidin-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities

Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis. Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol (1) delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. We previously identified selective RBP4 antagonists that dissociate circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis. However, the release of TTR by selective RBP4 antagonists may be associated with TTR tetramer destabilization and, potentially, TTR amyloid formation. We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers. Standout analogue (±)-44 possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay. This new class of bispecific compounds may be especially important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease associated with wild-type TTR misfolding.

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.